Cargando…

Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy eras

Between December 2005 and October 2009, FDA approved six targeted therapies shown to significantly extend survival for advanced renal cell carcinoma (RCC) patients in clinical trials. This study aimed to examine changes in survival between the pretargeted and targeted therapy periods in advanced RCC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Pengxiang, Wong, Yu‐Ning, Armstrong, Katrina, Haas, Naomi, Subedi, Prasun, Davis‐Cerone, Margaret, Doshi, Jalpa A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2015
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4735783/ https://www.ncbi.nlm.nih.gov/pubmed/26645975 http://dx.doi.org/10.1002/cam4.574

Ejemplares similares

Association of high cost sharing and targeted therapy initiation among elderly Medicare patients with metastatic renal cell carcinoma
por: Li, Pengxiang, et al.
Publicado: (2017)

Therapeutic Applications of Pretargeting
por: Verhoeven, Marjolein, et al.
Publicado: (2019)

Impact of Medicare Advantage Prescription Drug Plan Star Ratings on Enrollment before and after Implementation of Quality-Related Bonus Payments in 2012
por: Li, Pengxiang, et al.
Publicado: (2016)

Pretargeted Molecular Imaging and Radioimmunotherapy
por: Goldenberg, David M., et al.
Publicado: (2012)

Improvement of Radioimmunotherapy Using Pretargeting
por: Frampas, Eric, et al.
Publicado: (2013)

Comparison of the performance of the CMS Hierarchical Condition Category (CMS-HCC) risk adjuster with the charlson and elixhauser comorbidity measures in predicting mortality
por: Li, Pengxiang, et al.
Publicado: (2010)

Impact of Cost Sharing on Therapeutic Substitution: The Story of Statins in 2006
por: Li, Pengxiang, et al.
Publicado: (2016)

Clearing and Masking Agents in Pretargeting Strategies
por: Staudt, Markus, et al.
Publicado: (2023)

Pretargeted immunoscintigraphy in patients with medullary thyroid carcinoma.
por: Magnani, P., et al.
Publicado: (1996)

Pretargeting for imaging and therapy in oncological nuclear medicine
por: Bailly, Clément, et al.
Publicado: (2017)

Pretargeted imaging beyond the blood–brain barrier
por: Shalgunov, Vladimir, et al.
Publicado: (2022)

Pretargeted Nuclear Imaging and Radioimmunotherapy Based on the Inverse Electron-Demand Diels–Alder Reaction and Key Factors in the Pretargeted Synthetic Design
por: Qiu, Lin, et al.
Publicado: (2019)

Hybrid Imaging Agents for Pretargeting Applications Based on Fusarinine C—Proof of Concept
por: Summer, Dominik, et al.
Publicado: (2020)

Factors Associated with Antimicrobial Drug Use in Medicaid Programs
por: Li, Pengxiang, et al.
Publicado: (2014)

Assessment of US Pharmacies Contracted With Health Care Institutions Under the 340B Drug Pricing Program by Neighborhood Socioeconomic Characteristics
por: Lin, John K., et al.
Publicado: (2022)

Impact of Body Mass Index on Survival Outcomes of Patients with Metastatic Renal Cell Carcinoma in the Immuno-oncology Era: A Systematic Review and Meta-analysis
por: Takemura, Kosuke, et al.
Publicado: (2022)

Pretargeted radioimmunotherapy in the treatment of metastatic medullary thyroid cancer
por: Kraeber–Bodéré, F., et al.
Publicado: (2009)

Biotinylated magnetic nanoparticles for pretargeting: synthesis and characterization study
por: Chauhan, Ram Prakash, et al.
Publicado: (2011)

A pretargeting system for tumor PET imaging and radioimmunotherapy
por: Kraeber-Bodéré, Françoise, et al.
Publicado: (2015)

A Revisit to the Pretargeting Concept—A Target Conversion
por: Liu, Guozheng
Publicado: (2018)

Outcomes of axitinib versus sunitinib as first‐line therapy to patients with metastatic renal cell carcinoma in the immune‐oncology era
por: Numakura, Kazuyuki, et al.
Publicado: (2021)

Pathology-confirmed versus non pathology-confirmed cancer diagnoses: incidence, participant characteristics, and survival
por: van der Willik, Kimberly D., et al.
Publicado: (2019)

Effects of a pretarget distractor on saccade reaction times across space and time in monkeys and humans
por: Khan, Aarlenne Z., et al.
Publicado: (2016)

Pretargeted Imaging and Radioimmunotherapy of Cancer Using Antibodies and Bioorthogonal Chemistry
por: van de Watering, Floor C. J., et al.
Publicado: (2014)

Pretargeted Imaging beyond the Blood–Brain Barrier—Utopia or Feasible?
por: Lopes van den Broek, Sara, et al.
Publicado: (2022)

Racial and Ethnic Disparities in Long-Acting Injectable Antipsychotic Use in a National Sample of Medicare Beneficiaries With Schizophrenia
por: Li, Pengxiang, et al.
Publicado: (2023)

Real-world Treatment Patterns and Clinical Outcomes for Metastatic Renal Cell Carcinoma in the Current Treatment Era
por: Shah, Neil J., et al.
Publicado: (2023)

A Pretargeted Approach for the Multimodal PET/NIRF Imaging of Colorectal Cancer
por: Adumeau, Pierre, et al.
Publicado: (2016)

Adamantane/Cucurbituril: A Potential Pretargeted Imaging Strategy in Immuno-PET
por: Strebl, Martin G., et al.
Publicado: (2018)

Pretargeted PET Imaging of trans-Cyclooctene-Modified Porous Silicon Nanoparticles
por: Keinänen, Outi, et al.
Publicado: (2017)

A pretargeting nanoplatform for imaging and enhancing anti-inflammatory drug delivery
por: Khang, Min Kyung, et al.
Publicado: (2020)

Theranostic Pretargeting Drug Delivery and Imaging Platforms in Cancer Precision Medicine
por: Hapuarachchige, Sudath, et al.
Publicado: (2020)

Recent Advances in the Development of Tetrazine Ligation Tools for Pretargeted Nuclear Imaging
por: García-Vázquez, Rocío, et al.
Publicado: (2022)

High expression of sperm-associated antigen 5 correlates with poor survival in ovarian cancer
por: Zhang, Mei, et al.
Publicado: (2020)

Detecting hypoxia in vitro using (18)F-pretargeted IEDDA “click” chemistry in live cells
por: Allott, Louis, et al.
Publicado: (2021)

Influence of gene expression on survival of clear cell renal cell carcinoma
por: Berglund, Anders, et al.
Publicado: (2020)

Disparities in cancer survival and incidence by metropolitan versus rural residence in Utah
por: Hashibe, Mia, et al.
Publicado: (2018)

Feasibility of Affibody Molecule-Based PNA-Mediated Radionuclide Pretargeting of Malignant Tumors
por: Honarvar, Hadis, et al.
Publicado: (2016)

Tetrazine Carbon Nanotubes for Pretargeted In Vivo “Click‐to‐Release” Bioorthogonal Tumour Imaging
por: Li, He, et al.
Publicado: (2020)

Harnessing (64)Cu/(67)Cu for a theranostic approach to pretargeted radioimmunotherapy
por: Keinänen, Outi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_avaqq9jvv26rolejaunv9oc5ck